The average one-year price target for Roivant Sciences (NasdaqGS:ROIV) has been revised to $32.44 / share. This is an ...
WASHINGTON, DC – When billionaires are in the spotlight for their oversized influence in Washington, especially in the Trump administration, comes this news: Vivek Ramaswamy’s wealth has soared even ...
The 23 companies span cancer treatments, plant genetics and robotic lung devices. Combined, they pulled in just over $6.1 billion last year.
Generate Biomedicines has announced the pricing of its initial public offering, implying a market value of about $2 billion for the U.S. biotechnology firm. The company, which specializes in designing ...
Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...
Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 10:00 AM ESTCompany ParticipantsPavel Raifeld - ...
The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years.
New funding, which values the company at $730 billion before the investment, came from Amazon, SoftBank and Nvidia. The healthcare arm of Malaysian conglomerate Sunway is looking to raise about $736.3 ...